Nanatinostat

Lymphoproliferative Disorders

Viracta Therapeutics, Inc.Small moleculePhase 1/2Dormant

CC

42/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 27/ 100
Competitive Position: 89/ 100

Competitive context

28 Active assets in the Lymphoproliferative Disorders cohort.

Asset / Sponsor	Phase	Rating
Darbepoetin Alfa Mayo Clinic	Phase 3	BB
Epoetin Alfa Mayo Clinic	Phase 3	BB
Fludarabine Beijing Immunochina Medical Science & Technology Co., Ltd.	Phase 2	BB
Baclofen Alliance for Clinical Trials in Oncology	Phase 3	BB
Tabelecleucel Pierre Fabre Medicament	Phase 3	BB

View all 50 →

Same molecule, other indications

Nanatinostat is also rated in:

Epstein-Barr virus-associated lymphoproliferative disorderDormant

CCC

Indicative ·

49 / 100

Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderlyDormant

CC

Indicative ·

43 / 100

peripheral T-cell lymphoma, not otherwise specifiedDormant

CC

Indicative ·

43 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.